Takeda Pharmaceutical Company Profile (OTCMKTS:TKPYY)

About Takeda Pharmaceutical

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TKPYY
  • CUSIP:
Key Metrics:
  • Previous Close: $23.76
  • 50 Day Moving Average: $22.98
  • 200 Day Moving Average: $22.67
  • 52-Week Range: $1,563,644,000.00 - $20.32
  • Trailing P/E Ratio: 24.91
  • P/E Growth: 0.00
  • Market Cap: $37.15B
  • Outstanding Shares: 1,563,644,000
  • Beta: 0.31
Profitability:
  • Net Margins: 8.87%
  • Return on Equity: 10.64%
  • Return on Assets: 5.45%
Debt:
  • Debt-to-Equity Ratio: 0.40%
  • Current Ratio: 1.79%
  • Quick Ratio: 1.50%
Additional Links:
Companies Related to Takeda Pharmaceutical:

Analyst Ratings

Consensus Ratings for Takeda Pharmaceutical (OTCMKTS:TKPYY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2014$0.21ViewN/AView Earnings Details
2/5/2014Q4$0.29ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateHeadline
bloomberg.com logoTakeda's Biotech M&A Menu Is Long, Complex (OTCMKTS:TKPYY)
www.bloomberg.com - September 21 at 7:09 PM
finance.yahoo.com logoTakeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in Central Nervous System (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 21 at 7:01 AM
finance.yahoo.com logoTakeda and Zydus Cadila partner to address the global threat of Chikungunya (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 20 at 9:13 AM
seekingalpha.com logoEuropean Ad Comm backs Takeda's Ninlaro in multiple myeloma (OTCMKTS:TKPYY)
seekingalpha.com - September 16 at 11:17 AM
finance.yahoo.com logoFavorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology (OTCMKTS:TKPYY)
finance.yahoo.com - September 16 at 11:17 AM
thestreet.com logoWill Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals? (OTCMKTS:TKPYY)
www.thestreet.com - September 14 at 12:01 PM
finance.yahoo.com logoTakeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 12 at 9:48 AM
finance.yahoo.com logoTakeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003) (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 7 at 11:30 AM
ft.com logo[$$] Takeda signals global ambitions with dengue vaccine trial (OTCMKTS:TKPYY)
www.ft.com - September 7 at 11:30 AM
finance.yahoo.com logoTakeda Launches Wearable Digital Technology Pilot Program to Support Patients and Healthcare Providers with Inflammatory Bowel Disease Management (OTCMKTS:TKPYY)
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logo6 Drug Stocks in Focus as Zika Virus Fear Spreads (OTCMKTS:TKPYY)
finance.yahoo.com - September 6 at 9:35 AM
finance.yahoo.com logoTakeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 31 at 9:55 AM
finance.yahoo.com logoTakeda Announces Bold, New Access to Medicines Strategy (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 27 at 9:46 AM
capitalcube.com logoETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : August 24, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - August 24 at 7:34 PM
finance.yahoo.com logoTakeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 8 at 9:58 AM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 5, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - August 5 at 10:52 AM
finance.yahoo.com logoTakeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 1 at 6:59 AM
News IconTakeda to Now Focus on Three Therapeutic Areas (OTCMKTS:TKPYY)
www.pharmalive.com - July 29 at 8:03 PM
capitalcube.com logoETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : July 29, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - July 29 at 12:52 PM
bloomberg.com logoJapan’s Takeda Sees $725 Million in Costs From R&D Revamp (OTCMKTS:TKPYY)
www.bloomberg.com - July 29 at 4:38 AM
finance.yahoo.com logoTakeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance (OTCMKTS:TKPYY)
au.finance.yahoo.com - July 29 at 2:00 AM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - July 26 at 9:29 AM
bloomberg.com logoTakeda Said to Explore Sale of Chemicals Unit to Raise Cash (OTCMKTS:TKPYY)
www.bloomberg.com - July 21 at 7:49 AM
bloomberg.com logoStock Picker Wahei Takeda, Dubbed Japan’s Buffett, Dies at 83 (OTCMKTS:TKPYY)
www.bloomberg.com - July 21 at 4:35 AM
finance.yahoo.com logoTakeda Aims To Raise $500,000 for Team Challenge for Crohn's & Colitis (OTCMKTS:TKPYY)
finance.yahoo.com - July 15 at 1:00 PM
finance.yahoo.com logoTakeda and the Crohn's & Colitis Foundation of America Partner to Introduce 'IBD Unmasked' A First-of-its-Kind Awareness Campaign (OTCMKTS:TKPYY)
finance.yahoo.com - July 13 at 8:00 AM
finance.yahoo.com logoIBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community (OTCMKTS:TKPYY)
finance.yahoo.com - July 13 at 4:55 AM
seekingalpha.com logoTakeda nabs ex-U.S. rights to investigational stem cell treatment for Crohn's-related fistulas (OTCMKTS:TKPYY)
seekingalpha.com - July 6 at 9:32 AM
finance.yahoo.com logoTakeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma (OTCMKTS:TKPYY)
au.finance.yahoo.com - July 6 at 8:00 AM
finance.yahoo.com logoTakeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan (OTCMKTS:TKPYY)
au.finance.yahoo.com - July 5 at 8:00 AM
News IconReport Published: “Epithelial Ovarian Cancer – Pipeline Review, H1 2016” (OTCMKTS:TKPYY)
www.busbyway.com - July 1 at 10:26 AM
finance.yahoo.com logoTakeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis (OTCMKTS:TKPYY)
au.finance.yahoo.com - July 1 at 8:00 AM
News IconTakeda’s norovirus vaccine first to reach human trials (OTCMKTS:TKPYY)
www.foodsafetynews.com - June 25 at 11:27 AM
finance.yahoo.com logoTB Alliance and Takeda Announce Advancement of Joint Program Investigating Promising Compounds for Novel TB Therapies Through Global Health Innovative Technology Fund (OTCMKTS:TKPYY)
au.finance.yahoo.com - June 21 at 9:00 PM
News IconTri-Institutional Therapeutics Discovery Institute expands focus to include antibody drug discovery research (OTCMKTS:TKPYY)
newswire.rockefeller.edu - June 16 at 8:00 PM
4-traders.com logoTakeda Pharmaceutical : Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd. (OTCMKTS:TKPYY)
www.4-traders.com - June 16 at 8:00 PM
finance.yahoo.com logoTri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd. (OTCMKTS:TKPYY)
au.finance.yahoo.com - June 16 at 6:00 PM
News IconResearch report covers the Blood Cancer Treatment Market Growth, 2016-2026 (OTCMKTS:TKPYY)
www.medgadget.com - June 16 at 12:17 PM
bizjournals.com logoMersana to advance cancer killing drug to clinical trials with $33M investment (OTCMKTS:TKPYY)
www.bizjournals.com - June 16 at 11:45 AM
wsj.com logo[$$] Mersana Therapeutics Raises $33M Series C, Plans Cancer Clinical Trials (OTCMKTS:TKPYY)
www.wsj.com - June 16 at 7:30 AM
News IconCelgene joins DNDi's 'Drug Discovery Booster' (OTCMKTS:TKPYY)
www.eurekalert.org - June 15 at 7:41 PM
finance.yahoo.com logoEXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care (OTCMKTS:TKPYY)
finance.yahoo.com - June 11 at 1:31 PM
finance.yahoo.com logoTakeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions (OTCMKTS:TKPYY)
finance.yahoo.com - June 6 at 9:38 AM
News IconHusband blames pharmaceutical companies for wife's death (OTCMKTS:TKPYY)
louisianarecord.com - June 3 at 10:50 AM
finance.yahoo.com logoTrintellix (vortioxetine) Now Available in U.S. Pharmacies (OTCMKTS:TKPYY)
finance.yahoo.com - June 1 at 10:00 AM
feeds.reuters.com logoValeant rejected joint takeover bid from Takeda, TPG in spring: WSJ (OTCMKTS:TKPYY)
feeds.reuters.com - May 26 at 8:56 PM
feeds.reuters.com logoUPDATE 1-Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant (OTCMKTS:TKPYY)
feeds.reuters.com - March 15 at 8:58 AM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. Earnings Analysis: Q3, 2016 By the Numbers (OTCMKTS:TKPYY)
www.capitalcube.com - February 9 at 1:10 PM
bizjournals.com logoMersana plans human trials of first cancer drug by this summer (OTCMKTS:TKPYY)
www.bizjournals.com - February 8 at 4:10 PM
finance.yahoo.com logoFDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) (OTCMKTS:TKPYY)
finance.yahoo.com - February 3 at 8:35 PM

Social

Takeda Pharmaceutical (OTCMKTS:TKPYY) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff